Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors

NCT06933069 | Recruiting Phase 1

• 1 other identifier: CMAB017-001
• Study Type: interventional
• Target: 55
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multicenter, open-lable phase Ia clinical study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor activity of CMAB017 in advanced malignant solid tumors.

Conditions

Solid Malignancies

Outcome Measures

Primary Outcomes (2)

• Dose Limiting Toxicities，DLT

  Up to 12 weeks

• Maximal Tolerated Dose，MTD

  Up to 12 weeks

Secondary Outcomes (9)

• Safety: The severity and incidence of other adverse events (AE) outside DLT

  Date of the first dosing of study drug to 28 days post last dose of study drug.

• Peak blood Concentration (Cmax)

  Day 1 to Day 15

• Trough blood Concentration (Cmin)

  Day 1 to Day 15

• Steady-state area under the plasma concentration versus time curve (AUC0-τ)

  Day 1 to Day 15

• Half life (t1/2)

  Day 1 to Day 15

Study Arms (1)

CMAB017

EXPERIMENTAL

CMAB017 100 mg intravenous (IV) solution for Injection every 3 weeks (Q3W) or every 2 weeks (Q2W)

Drug: CMAB017

Interventions

CMAB017 DRUG

CMAB017 was administered at a preset dose, and body weight was measured before each study dose; if body weight changed ≥10% from baseline, the dose should be recalculated. Administration was by intravenous infusion: for doses ≤1000 mg, intravenous infusion lasted 60±5 min; for doses \>1000 mg, intravenous infusion lasted 90±5 min.

CMAB017

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• fully understand and agree to sign the Informed Consent Form (ICF);
• histologically or cytologically confirmed, inoperable, locally advanced, recurrent or metastatic malignant solid tumors, including but not limited to head and neck squamous carcinoma, RAS wild-type colorectal cancer, esophageal squamous carcinoma, etc., for which the patient has failed standard treatment, does not have standard treatment, or refuses standard treatment;
• age 18\~75 years old, gender is not limited;
• Eastern Cooperative Oncology Group (ECOG) score ≤1;
• expected survival ≥ 3 months;
• presence of at least one evaluable lesion according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 (bone-only metastases or central nervous system-only metastases will not be accepted as evaluable lesions); starting from 6 mg/kg Q3W, 4 mg/kg Q2W after the start of the dose group, presence of at least one measurable lesion; and dose groups, at least one measurable lesion is present (bone-only metastases or CNS-only metastases will not be accepted as measurable lesions);
• females of childbearing potential must be non-lactating and have a negative serum pregnancy test within 1 week prior to the first infusion and agree to use effective contraception from the time of signing the ICF until 6 months after the last infusion; male subjects must agree to use effective contraception from the time of signing the ICF until 6 months after the last infusion;
• Blood routine and liver and kidney functions during the screening period meet the following conditions:
• Blood routine: neutrophils ≥1.5×109/L; platelets ≥75×109/L; hemoglobin ≥90 g/L;
• Liver function: alanine aminotransferase and aspartate aminotransferase ≤3×ULN (both should be ≤5×ULN for those with tumor liver metastasis); total bilirubin ≤1.5×ULN; ③ Coagulation function: activated partial thromboplastin time (APTT) ≤1.5×ULN; international normalized ratio (INR) ≤1.5×ULN (for patients not receiving anticoagulation therapy; APTT or INR of subjects receiving anticoagulation therapy should be within the expected therapeutic range of anticoagulant drugs); ④ Renal function: blood creatinine ≤ 1.5 x ULN; if creatinine \> 1.5 x ULN, creatinine clearance (Ccr) \> 50mL/min is required (calculated according to the Cockcroft-Gault formula).

You may not qualify if:

• With known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may be enrolled in the study provided that they have been clinically stable for at least 2 weeks, have no evidence of new or expanding brain metastases, and have discontinued steroids within 2 weeks prior to the infusion of the trial drug. Stability of brain metastases should be determined prior to the first dose of the trial drug infusion. Patients with asymptomatic brain metastases (i.e., no neurologic symptoms, no need for medication, and no lesion with a longest diameter \>1.5 cm) may be enrolled, but will be required to undergo periodic imaging;
• subjects with grade ≥2 corneal abnormalities present at screening;
• adverse effects of prior antineoplastic therapy that have not recovered to a CTCAE 5.0 grade rating of ≤ grade 1 or to the level specified in the entry criteria (except for toxicities judged by the investigator to be of no safety risk, e.g., alopecia, grade 2 peripheral neurotoxicity, and hypothyroidism stabilized by hormone replacement therapy)
• other malignancies within the previous 5 years, usually with the exception of the following: a. any other aggressive malignancy (for which the subject has had adequate treatment) for which disease-free status has persisted for \>3 years and which, in the investigator's assessment, would not interfere with the assessment of oncologic efficacy; and b. cured basal cell or squamous cell skin cancers, superficial bladder cancers, and locally curable cancers such as prostate, cervical, or breast cancer in situ;
• a history of immunodeficiency, including a positive HIV antibody test, or other acquired or congenital immunodeficiency disease, or a history of organ transplantation
• interstitial lung disease that is symptomatic or may interfere with pulmonary toxicity monitoring associated with the test drug;
• a history of serious cardiovascular or cerebrovascular disease, including, but not limited to: severe cardiac rhythm or conduction block, such as ventricular arrhythmia requiring clinical intervention, degree III atrioventricular block, etc.; QTc intervals \> 480 ms on 12/15 lead ECG at rest; acute coronary syndrome, congestive heart failure, aortic dissection, stroke within 6 months prior to the first infusion or other grade 3 or higher cardiovascular events; NYHA cardiac function classification ≥ grade II or LVEF \<50%; clinically uncontrollable hypertension;
• any of the following within 4 weeks prior to the first trial drug infusion:
• Has had major surgery (defined as surgery requiring general anesthesia).
• has participated in a clinical trial and received investigational treatment or used an investigational device.
• Undergoing or planning other antineoplastic therapy outside of this study protocol (certain specific antineoplastic agents may be excluded from the 4 weeks prior to drug infusion, e.g., oral fluorouracil ≥ 2 weeks; mitomycin C, nitrosoureas ≥ 6 weeks; and small molecule targeted therapy ≥ 2 weeks);
• any of the following within 2 weeks prior to the first trial drug infusion:
• Having had localized palliative radiotherapy.
• Received herbal/proprietary Chinese medicines that are clearly indicated for the treatment of oncological indications.
• Has had minor surgery (other than major surgery, but diagnostic procedures such as incision and/or needle core biopsy are not considered minor surgery).

Sponsors & Collaborators

• Taizhou Mabtech Pharmaceutical Co.,Ltd: lead

Study Sites (1)

Shanghai East Hospital

Shanghai, 200123, China

RECRUITING

Central Study Contacts

Ye Guo Principal Investigator

CONTACT

021-38804518-22132; pattrick.guo@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 1, 2025
• First Posted: April 18, 2025
• Study Start: June 9, 2025
• Primary Completion (Estimated): May 31, 2026
• Study Completion (Estimated): May 31, 2026
• Last Updated: September 11, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)